Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alpha-interferon plus anti-PD-1 adjuvant therapy in HCC with portal vein tumor thrombus after hepatectomy
ChiCTR2000037461Phase 2Not yet recruiting
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Oct 2020
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of interferon alfa in hepatocellular carcinoma (HCC) (2 arms), sponsored by Fudan University Shanghai Cancer Center. Primary endpoints: Recurrence-free survival (RFS) and Overall survival (OS). Planned start Oct 2020; status: not yet recruiting.
02
Drugs
interferon alfa
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2000037461.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000037461.